{"id":"https://openalex.org/W6998550496","doi":null,"title":"Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer","display_name":"Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer","alternate_titles":[],"publication_year":2023,"publication_date":"2023-08-22","ids":{"openalex":"https://openalex.org/W6998550496"},"language":"en","primary_location":{"id":"pmh:oai:works.bepress.com:thomas_yang-1069","doi":null,"is_oa":false,"landing_page_url":"https://works.bepress.com/thomas_yang/37","pdf_url":null,"source":{"id":"https://openalex.org/S4377196356","display_name":"Scholarly Commons (Embry\u2013Riddle Aeronautical University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I84475105","host_organization_name":"Embry\u2013Riddle Aeronautical University","host_organization_lineage":["https://openalex.org/I84475105"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Thomas Yang","raw_type":"text"},"parent_works":[],"lineage":["https://openalex.org/W6998550496"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Sabari, JK","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sabari, JK","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Shu, CA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shu, CA","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Park, K","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Park, K","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Leighl, N","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leighl, N","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Mitchell, P","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mitchell, P","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Kim, S","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kim, S","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lee, J","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee, J","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Kim, D","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kim, D","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Viteri, S","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Viteri, S","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Spira, A","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Spira, A","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Han, J","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Han, J","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062111870","display_name":"Jos\u00e9 Manuel Trigo","orcid":"https://orcid.org/0000-0002-4489-2683","observed_orcids":["https://orcid.org/0000-0002-4489-2683"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Trigo, J","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lee, CK","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee, CK","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lee, KH","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee, KH","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090329560","display_name":"Nicolas Girard","orcid":"https://orcid.org/0000-0001-9909-2299","observed_orcids":["https://orcid.org/0000-0001-9909-2299"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Girard, N","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Yang, T","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yang, T","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Goto, K","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Goto, K","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Sanborn, Rachel E","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sanborn, Rachel E","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Yang, JC","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yang, JC","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Xie, J","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xie, J","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027461408","display_name":"Amy Roshak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roshak, A","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Thayu, M","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thayu, M","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Knoblauch, RE","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Knoblauch, RE","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Cho, BC","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cho, BC","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/amivantamab","display_name":"amivantamab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/egfr-exon-20-insertion-mutation","display_name":"EGFR exon 20 insertion","score":0.968999981880188},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9710000157356262},{"id":"https://openalex.org/keywords/egfr-met-bispecific-antibody","display_name":"EGFR-MET bispecific antibody","score":0.9490000009536743},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7039999961853027},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.6930000185966492},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6940000057220459},{"id":"https://openalex.org/keywords/met-mutations","display_name":"MET mutations","score":0.42500001192092896},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.4480000138282776},{"id":"https://openalex.org/keywords/recist-1-1","display_name":"RECIST 1.1","score":0.5960000157356262},{"id":"https://openalex.org/keywords/breakthrough-therapy-designation","display_name":"breakthrough therapy designation","score":0.4009999930858612}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8482999801635742},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6535000205039978},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6481999754905701},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6043999791145325},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5759000182151794},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5400999784469604},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4422999918460846},{"id":"https://openalex.org/C36823959","wikidata":"https://www.wikidata.org/wiki/Q373027","display_name":"Exon","level":3,"score":0.41999998688697815},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4196999967098236},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4043000042438507},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.3628999888896942},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.35670000314712524},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.34060001373291016},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.3384000062942505},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.3361000120639801},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.32330000400543213},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.32170000672340393},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.31470000743865967},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.2867000102996826},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.2865999937057495},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.2856000065803528},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.2847000062465668},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.28439998626708984},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.28130000829696655},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.27379998564720154},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.2727000117301941},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.27090001106262207},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.2615000009536743}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:works.bepress.com:thomas_yang-1069","doi":null,"is_oa":false,"landing_page_url":"https://works.bepress.com/thomas_yang/37","pdf_url":null,"source":{"id":"https://openalex.org/S4377196356","display_name":"Scholarly Commons (Embry\u2013Riddle Aeronautical University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I84475105","host_organization_name":"Embry\u2013Riddle Aeronautical University","host_organization_lineage":["https://openalex.org/I84475105"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Thomas Yang","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9789000153541565,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3191219220","https://openalex.org/W3138952535","https://openalex.org/W3030280670","https://openalex.org/W4327944896","https://openalex.org/W7162859771","https://openalex.org/W3190722538","https://openalex.org/W6977086540","https://openalex.org/W4388533597","https://openalex.org/W3138438276","https://openalex.org/W3167677215"],"abstract_inverted_index":{"Introduction":[0],"Despite":[1],"sharing":[2],"similar":[3],"tumor":[4],"biology":[5],"to":[6,122,208,437,451,467],"other":[7],"epidermal":[8],"growth":[9],"factor":[10],"receptor":[11],"(EGFR)":[12],"mutant":[13],"non-small":[14],"cell":[15],"lung":[16],"cancer":[17],"(NSCLC)":[18],"tumors,":[19],"no":[20,46],"targeted":[21],"therapies":[22],"have":[23],"been":[24],"approved":[25],"for":[26,42,86,135,174],"NSCLC":[27,94,121,156,179,462],"harboring":[28],"EGFR":[29,70,92,361,460],"Exon":[30],"20":[31],"insertion":[32],"mutations":[33,76],"(Exon20ins).":[34],"The":[35,113,139,215,286,431],"standard":[36],"of":[37,89,130,148,245,260,310,360,366,411,433],"care":[38],"remains":[39],"platinum-based":[40,96,185],"chemotherapy":[41,491],"the":[43,87,104,108,124,144,159,166,190,209,225,373,376,479,493],"front-line,":[44],"with":[45,61,91,119,152,177,279,319,369,417,454,459,490],"clear":[47],"subsequent":[48],"options":[49],"available.":[50],"Amivantamab":[51,448],"(JNJ-61186372)":[52],"is":[53,172,496],"a":[54,257,308,358,469],"novel,":[55],"fully":[56],"human":[57],"EGFR-MET":[58],"bispecific":[59],"antibody":[60],"immune":[62],"cell-directing":[63],"activity":[64],"that":[65],"targets":[66],"activating":[67],"and":[68,77,79,146,154,171,192,252,339,364,390,401,420,440,444,465],"resistance":[69],"mutations,":[71],"as":[72,74],"well":[73],"MET":[75],"amplifications,":[78],"has":[80],"received":[81],"FDA":[82],"Breakthrough":[83],"Therapy":[84],"Designation":[85],"treatment":[88,449],"patients":[90,118,151,176,458,476],"Exon20ins":[93,105,178,461],"after":[95],"chemotherapy.":[97],"Here":[98],"we":[99],"present":[100],"updated":[101],"results":[102],"on":[103,183],"cohort":[106],"from":[107],"CHRYSALIS":[109],"study":[110],"(NCT02609776).":[111],"Methods":[112],"dose":[114,128,140,438],"escalation":[115],"phase":[116,126,142,354,482],"enrolled":[117],"advanced":[120],"determine":[123],"recommended":[125],"2":[127,248],"(RP2D)":[129],"1050":[131],"mg":[132,134],"(1400":[133],"\u226580":[136],"kg)":[137],"amivantamab.":[138],"expansion":[141],"assessed":[143,164],"safety":[145,471],"efficacy":[147,453],"amivantamab":[149,370,487],"in":[150,322,409,457,473,488,492,497],"EGFR-":[153],"MET-mutant":[155],"treated":[157,188,368,477],"at":[158,189,194,307,325,372,478],"RP2D.":[160,480],"Disease":[161],"response":[162,268,284],"was":[163,219,231,247,271,296,331,343,442],"by":[165],"investigator":[167],"per":[168],"RECIST":[169],"v1.1":[170],"presented":[173],"those":[175],"who":[180],"had":[181,193],"progressed":[182],"prior":[184,207,243],"chemotherapy,":[186],"were":[187,237,240,254,305,382,396,407,414,429],"RP2D,":[191],"least":[195],"3":[196,483],"post-baseline":[197],"disease":[198,293],"assessments":[199],"(18":[200],"weeks)":[201,295],"or":[202,205,291],"discontinued,":[203],"progressed,":[204],"died":[206],"3rd":[210],"assessment":[211],"(the":[212],"Post-Platinum":[213,226],"Cohort).":[214],"data":[216],"cutoff":[217],"date":[218],"8":[220],"Jun":[221],"2020.":[222],"Results":[223],"In":[224],"Cohort":[227],"(n=81),":[228],"median":[229,242,258,309,340],"age":[230],"62":[232,301],"(42":[233],"\u2013":[234,250,264,277,302,316,337,349],"84),":[235],"59%":[236],"women,":[238],"49%":[239],"Asian,":[241],"lines":[244,365],"therapy":[246],"(1":[249],"7),":[251],"53%":[253],"never-smokers.":[255],"At":[256],"follow-up":[259],"6.5":[261],"months":[262,312,333,345],"(1.1":[263],"29.3),":[265],"investigator-assessed":[266],"overall":[267,341],"rate":[269,289],"(ORR)":[270],"36%":[272],"(29/81;":[273],"95%":[274,299],"CI,":[275,300,314,335,347],"25":[276],"47),":[278],"all":[280,353],"responders":[281],"achieving":[282],"partial":[283],"(PR).":[285],"clinical":[287],"benefit":[288],"(\u2265PR":[290],"stable":[292],"\u226511":[294],"73%":[297],"(59/81;":[298],"82).":[303],"Responses":[304],"durable":[306,455],"6.8":[311],"(95%":[313,334,346],"5.0":[315],"not":[317,350],"reached)":[318],"ongoing":[320],"responses":[321,456],"18/29":[323],"(longest":[324],"16+":[326],"months).":[327],"Median":[328],"progression-free":[329],"survival":[330,342],"8.3":[332],"5.5":[336],"12.7)":[338],"22.8":[344],"14.0":[348],"reached).":[351],"Among":[352],"1":[355],"patients,":[356],"across":[357],"variety":[359],"genomic":[362],"alterations":[363],"therapy,":[367],"monotherapy":[371],"RP2D":[374],"(n=258),":[375],"most":[377,424],"common":[378],"adverse":[379],"events":[380],"(AEs)":[381],"rash":[383,418],"(78%),":[384],"infusion":[385],"related":[386],"reaction":[387],"(IRR;":[388],"65%),":[389],"paronychia":[391],"(40%).":[392],"Additional":[393],"EGFR-related":[394],"AEs":[395,406,435],"stomatitis":[397],"(19%),":[398,400],"pruritus":[399],"diarrhea":[402],"(11%).":[403],"Grade":[404],"\u22653":[405],"reported":[408],"39%":[410],"patients;":[412],"14%":[413],"considered":[415],"treatment-related,":[416],"(3%)":[419],"IRR":[421],"(2%)":[422],"being":[423],"frequent.":[425],"No":[426],"treatment-related":[427,434],"deaths":[428],"reported.":[430],"incidence":[432],"leading":[436],"reduction":[439],"discontinuation":[441],"10%":[443],"3%,":[445],"respectively.":[446],"Conclusion":[447],"led":[450],"promising":[452],"post-platinum":[463],"doublet":[464],"continues":[466],"demonstrate":[468],"manageable":[470],"profile":[472],"over":[474],"250":[475],"A":[481],"study,":[484],"PAPILLON,":[485],"evaluating":[486],"combination":[489],"front-line":[494],"setting":[495],"planning":[498],"stages.":[499]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W6998550496","counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2025-10-10T00:00:00"}
